SK Biopharma preps Korea’s debut 2020 IPO, eyes $780m
SK Biopharmaceuticals is set to reopen the South Korean IPO market with a W959.3bn ($779.9m) listing, according to a source close to the deal.
The company, a subsidiary of Korean conglomerate SK Group, has hired Citi, Morgan Stanley and NH Investment & Securities as lead managers to run its listing.It is offering 19.5m shares, equal to 25% of its outstanding share capital. The float is a mix of 13.3m new and ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org